Neurofeedback to Treat Depression - 2
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- University of Pennsylvania
- Study ID
- NCT07159061
- Status
- Recruiting
Conditions
- Major Depressive Disorder (MDD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Active Closed Loop Real Time fMRI Neurofeedback — BEHAVIORALActive neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
- Sham Closed Loop Real Time fMRI Neurofeedback — BEHAVIORALSham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
Study Details
This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD. This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.
Key Dates
- Start date
- Nov 21, 2025
- Status verified
- Dec 2025
- Primary completion
- Nov 21, 2028
- Completion
- Dec 1, 2028
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Active Comparator: Active NeurofeedbackR33 Phase: Three training sessions. Each training session contains 32 minutes of active neurofeedback runs.
- Sham Comparator: Sham Comparator: Sham NeurofeedbackR33 Phase: Three training sessions. Each training session contains 32 minutes of sham (placebo) neurofeedback runs.
Primary Outcome Measure
Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: 3 months ]
Central Contacts
- Yvette Sheline, M.D.(215) 746-2637
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Center for Neuromodulation in Depression and Stress | Philadelphia | Pennsylvania | 19104 | Yvette Sheline, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Philadelphia, PA
Related Studies
- Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of KetamineEARLY_PHASE1 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPHASE3 · Recruiting · Cybin IRL Limited · Birmingham, Alabama
- Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderPHASE3 · Recruiting · Vanda Pharmaceuticals · Phoenix, Arizona
- A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)PHASE2 · Recruiting · Seaport Therapeutics · Chino, California